According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
EARS stock traded down $0.01 during mid-day trading on Thursday, hitting $2.71. 69,037 shares of the stock were exchanged, compared to its average volume of 155,115. The business has a fifty day moving average price of $2.70 and a 200 day moving average price of $1.85. Auris Medical has a 12 month low of $2.41 and a 12 month high of $39.40. The stock has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.18 and a beta of -0.50.
Auris Medical Company Profile
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Read More: What is the strike price in options trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.